Date |
Company |
Amount |
Funding type |
Investors |
Therapeutic area |
Type of Information |
2018-01-29 |
Iovance Biotherapeutics (USA - CA) |
$172.5 million |
private placement |
|
Cancer - Oncology |
Private placement |
2018-01-23 |
Tmunity Therapeutics (USA - PA) |
$ 100 million |
series A financing round |
Ping An Ventures (China) Parker Institute for Cancer Immunotherapy (USA - CA) Gilead Sciences (USA - CA) Be The Match BioTherapies University of Pennsylvania (USA - PA) Lilly Asia Ventures (China) |
Cancer - Oncology - Autoimmune diseases - Infectious diseases |
Series A financing round |
2018-01-23 |
Skyhawk Therapeutics (USA - MA) |
$ 8 million |
financing round |
Tim Disney, the Duke of Bedford, Alexandria Venture Investments (USA - MA) and other undisclosed private investors |
Cancer - Oncology - Neurological diseases |
Financing round |
2018-01-23 |
Ultragenyx Pharmaceutical (USA - CA) |
$250 million |
private placement |
|
Rare diseases - Genetic diseases |
Private placement |
2018-01-22 |
Avexis (USA - IL) |
$431.9 million |
private placement |
|
Rare diseases - Genetic diseases - Neuromuscular diseases |
Private placement |
2018-01-22 |
Beigene (China) |
$800 million |
private placement |
|
Cancer - Oncology |
Private placement |
2018-01-16 |
Arbutus Biopharma (Canada) |
US$116.4 million |
private placement |
Roivant Sciences (CH - USA) |
Infectious diseases |
Private placement |
2018-01-08 |
Bluebird Bio (US - MA) |
$651.3 million |
private placement |
|
Rare diseases - Genetic diseases |
Private placement |
2018-01-05 |
Advicenne (France) |
€27.8 million |
IPO |
|
Rare diseases - Genetic diseases - Pediatric diseases |
IPO |
2018-01-04 |
Enterome Bioscience (France) |
€40 million |
loan |
European Investment Bank (EIB) |
Liver diseases - Hepatic diseases - Inflammatory diseases - Digestive diseases - Cancer - Oncology |
Loan |
2018-01-04 |
Enterome Bioscience (France) |
€32 million ($38.5 million) |
series D financing round |
BMS (USA - NY) Principia SGR (Italy) Health For Life Capital (Seventure) (France) Lundbeckfond Venture (Denmark) Nestlé Health Science (Switzerland) Omnes Capital (France) |
Liver diseases - Hepatic diseases - Inflammatory diseases - Digestive diseases - Cancer - Oncology |
Series D financing round |
2018-01-04 |
Acticor Biotech (France) |
€3.9 million |
financing round |
Primer Capital (Russia) Anaxago (France) CapDecisif Management (France) private investors |
Cerebrovascular diseases |
Financing round |
2018-01-04 |
BioNTech (Germany) |
$270 million |
series A financing round |
Redmile Group (USA - CA) Janus Henderson Investors (UK) Invus (USA - NY) Fidelity Management & Research Company (USA - MA) European family offices. The Struengmann Family Office |
Cancer - Oncology - Infectious diseases |
Series A financing round |
2018-01-02 |
Osmia Pharmaceutical (Sweden) |
108 million SEK |
loan |
Arwidsro Investment (Sweden) |
Cancer - Oncology |
Loan |
2017-12-29 |
Armo BioScience |
|
IPO |
|
Cancer - Oncology |
IPO |
2017-12-22 |
Sagetis Biotech (Spain) |
undisclosed |
grant |
Duchenne Parent Project España (Spain) |
Cancer - Oncology - Rare diseases |
Grant |
2017-12-21 |
Taris Biomedical (USA - MA) |
$ 25 million |
series B financing round |
BMS (USA - NY) Flagship Pioneering (USA - MA) Norma Investments (UK) Polaris Partners (USA - MA) RA Capital Management (USA - MA) Yonghua Capital (China) |
Cancer - Oncology |
Series B financing round |
2017-12-20 |
Orchard Therapeutics (UK) |
$110 million (£85 million) |
series B financing round |
Baillie Gifford (UK) ORI Capital Temasek (Singapore) Cowen Healthcare Investments (USA - NY) Juda Capital, Pavilion Capital (USA - NY) RTW Investments (USA - NY) 4BIO Capital (UK) F-Prime Capital (USA -MA) UCL Technology Fund (UK) |
Rare diseases - Genetic diseases |
Series B financing round |
2017-12-15 |
Blueprint Medicines (USA - MA) |
$325.5 million |
private placement |
|
|
Private placement |
2017-12-15 |
Univercells (Belgium) |
€3 million ($3.56M) |
series A financing round |
Takeda Ventures, US and EU private investors |
Technology - Services |
Series A financing round |